Category Archives: Medicine Wellness Health

Medicine Wellness Health

NEW Natural Chef Course in Dublin

Jumpstart your career at the College of Naturopathic Medicine

NEW Natural Chef Course in Dublin

Dublin, Ireland: CNM, The College of Naturopathic Medicine“s, new Natural Chef course meets the demands of society“s growing awareness of foods that support and promote health, and increased interest in nutritious dining options that entice with taste and innovative cooking. The CNM Natural Chef is a 3-part diploma course covering what you need to succeed as a Natural Chef; from how the digestive process works, to steps for building your culinary career! Training consists of 420 hours of life-changing education, followed by an internship of 100 additional hours.

At CNM, Natural Chef Students are taught to prepare delicious gourmet meals that focus on nutritional value, keeping to whole, organic, fresh and minimally processed foods that are procured in season. And, as no single dietary regimen is appropriate for everyone, students learn how individualised food plans can enhance health.

This course is suitable for all foodies, aspiring chefs and skilled cooks. Whether you want to learn how to prepare healthy and delicious food for your family, or you want to turn your skills and knowledge into a successful career in an expanding culinary field.

Diploma Course includes:
-Food fundamentals
-Natural Chef techniques
-Food for Health
-Therapeutic menu & recipe writing
-Building a culinary career

Learn more! Attend a FREE Open Evening in Dublin
Call 01 672 5036 or book online www.naturopathy.ie

About The College of Naturopathic Medic: The College of Naturopathic Medicine (CNM) is Ireland“s largest and longest established training provider for Nutrition Courses, Herbal Medicine Courses and Acupuncture Courses with colleges in Dublin, Cork and Galway. CNM has additional colleges throughout the UK and USA.

About The College of Naturopathic Medic: The College of Naturopathic Medicine (CNM) is Ireland“s largest and longest established training provider for Nutrition Courses, Herbal Medicine Courses and Acupuncture Courses with colleges in Dublin, Cork and Galway. CNM has additional colleges throughout the UK and USA.

Contact
CNM
Can Behan
Townshend street 215
6 Dublin
Phone: 0892407292
E-Mail: pr@naturopathy.ie
Url: https://www.naturopathy.ie/

Medicine Wellness Health

Medical center in Düsseldorf for international patients

Multidisciplinary medical network Medplus Nordrhein in Düsseldorf offers medical tourists specific values. All doctors work hand in hand, so patients get all relevant examinations and results in a brief span.

Medical center in Düsseldorf for international patients

Medplus Nordrhein is a multidisclipinary medical network in Düsseldorf.

Düsseldorf has globally high reputation as a medical location with around 2000 doctors and many hospitals. According to this international medical tourists come to Düsseldorf to make use of high-end medical services. „Medical tourists are attractive but demanding. Next to top medical quality doctors are asked to understand their cultural demands and to offer services meeting their wishes. It begins with opening hours and extend to language capabilities“, Dr. Adrian Flohr says. The gynecologist is managing director of Medplus Nordrhein ( www.medplus-nordrhein.de), a multi-disciplinary medical network with doctors from many medical professions, therapists, diabetes and food advisors in Düsseldorf and Krefeld. Medplus Nordrhein focuses on cross-linking all medical competences and services, experts are working closely together as a health partner at the patients“ side.

„That goes for international patients, too, who visit our center on a regular basis for multidisciplinary treatment. Especially patients from Russia, the former CIS-countries and from the Arabian countries asked for advice and treatment.“ Some Doctors and assistants are fluent in Russian, communication in English is a standard. „According to this we can realize the whole process from international agreements on appointments to the discussion of treatment results in several languages. Our international patients appreciate that“, Dr. Adrian Flohr states.

Diabetologist Dr. Jolanda Schottenfeld-Naor points out that among other services international patients asked especially for check-up treatments. Medplus Nordrhein doctors focus on early diagnosis, prevention and interdisciplinary examination concepts. „Check-ups are becoming more and more important. As a medical network we conduct coherent treatments from all relevant professions to achieve a full picture of the patient“s health status.“ Dr. Jolanda Schottenfeld-Naor runs a focused diabetes surgery and is consulted for check-ups with diabetes connection and offers diagnosis, advisory and therapy for all forms of diabetes, adiposity, arterial hypertonia, lipid metabolic disorders and all accompanying and secondary disorders.

Cardiologist Dr. Avner Horowitz says that all doctors work hand in hand and that the offices build a „small hospital“. „Thanks to our specialized network we can answer to our patients needs. So our check-up treatment always is a full service measure. We stand for close and quick communication and consecutive medical actions. That is a benefit for patients coming to Düsseldorf for treatment and advice. They get all relevant examinations and results in a brief span and can go home with package of measures to better their health or strengthen their health level.“

And eye doctor Dr. Oded Horowitz refers to the long opening hours. As a center the surgery for internal and general medicine and diabetology opens on Mondays and Thursdays from 8 to 6pm, on Tuesdays from 8 to 7pm, on Wednesdays and Fridays from 8 to 4pm and on Saturdays from 8 to 12am. „Our patients get more flexibility and can plan their schedule more individually. At the same time the long working hours enables all doctors to communicate very closely in the patient“s sense.“

About Medplus Nordrhein
Medplus Nordrhein is a multidisciplinary medical network since 2010 with doctors from many medical professions, therapists, diabetes and food advisors in Düsseldorf and Krefeld. Medplus Nordrhein consists of the surgeries of Dr. Adrian Flohr & Colleagues (gynecology), Dr. Avner Horowitz (internal medicine and cardiology), Dr. Oded Horowitz / Colleagues (eye specialist) and Dr. Jolanda Schottenfeld-Naor (internal medicine and diabetology). Medplus Nordrhein focuses on cross-linking all medical competences and services; experts are working closely together as a health partner at the patients“ side. Medplus Nordrhein doctors focus on early diagnosis, prevention and interdisciplinary examination concepts. Some Doctors and assistants are fluent in Russian; communication in English is a standard. According to this Medplus Nordrhein can realize the whole process from international agreements on appointments to the discussion of treatment results in several languages. More information: www.medplus-nordrhein.de

Contact
Medplus Nordrhein
Christian Lenski
Oststraße 51
40211 Düsseldorf
Phone: 0211 16888939
E-Mail: verwaltung@medplus-nordrhein.de
Url: http://www.medplus-nordrhein.de

Medicine Wellness Health

Definiens strengthens position as global service provider in biopharma

Jacques Corriveau joining as General Manager North America

Munich, Germany – November 13, 2017 – Definiens, the leader in Tissue Phenomics® announced the strengthening of its global commercial leadership team by appointing Jacques Corriveau as Vice President and General Manager North America. This addition will support the company´s strategic shift and further growth as an end-to-end transformative service provider for biomarker programs in immuno-oncology.
Jacques brings more than 15 years´ experience in commercial leadership within the life science and healthcare market. Before joining Definiens, he held various executive positions developing and executing global go-to-market strategies for disruptive technologies in both research and clinical markets. With this addition, Definiens strengthens its strategic focus and position of its US headquarters in Boston, MA, a key center of permanent business growth and future expansion in the North American region.
As a service-centric company, Definiens´ recently enhanced services portfolio sets a new milestone for biomarker-dependent drug development in immuno-oncology. Definiens´ unsurpassed offering of biomarker discovery solutions guides preclinical and clinical trial programs in immuno-oncology across the globe, allowing clients to expedite trial programs and to find more predictive biomarkers for new therapies. Definiens´ unique ability to integrate spatial dependencies and multi-omics analytics of immune and tumor cells in a common context, positions Definiens at the forefront of biomarker development – from research and early clinical through companion diagnostics.
Jacques Corriveau commented, „I am thrilled to be part of the Definiens team particularly now as we see the convergence of genomic analysis and tissue image analysis to rapidly expand the pace of personalized medicine. Definiens has the right technology and expertise to significantly reduce time to results in early clinical trials and select the right patients for advanced trials. This ultimately leads to more successful clinical programs. Our goal is to support pharmaceutical companies with biological insights and to help them to not only generate data but come to the right conclusion and decisions for the benefit of cancer patients. We have significantly strengthened our capabilities to provide strong value to customers and patients leveraging Tissue Phenomics®.“
Definiens Chief Commercial officer Michael Rasche added: „We are excited to have Jacques joining our global commercial team. His experience in the immuno-oncology space, combined with his outstanding people leadership skills, are a perfect cultural and strategical fit for Definiens and our ambition to continue our steep growth and team expansion in North America. Our clients, partners and our regional team will equally benefit from his expertise.“

Definiens once again proves its commitment to put an unprecedented team of leading experts in place to drive innovation in immuno-oncology and to being a key partner with expertise to support tissue-based oncology biomarker programs from start to finish.

About Definiens
Improving patient lives by unlocking the tissue phenome
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune
system for that purpose. Our mission is to accelerate breakthroughs in immuno-oncology by helping
pharmaceutical researchers better leverage tissue-based information through Definiens Tissue Phenomics® –
technology. Our expertise accelerates and deepens understanding of disease biology and immune system
mechanisms and allows to bring multi-omics data into a cancer-relevant context, which facilitates the
translation of new insights into novel therapies and treatment strategies. Our vision is to create unique and
actionable patient profiles through harmonized biomarkers for an individualized standard of care, where
patients experience fewer side effects and live longer. Definiens“ proven technology has been used in
thousands of projects, yielding results that have accelerated drug development and produced over 650 peerreviewed
publications.
Definiens is a member of the AstraZeneca group providing products and services to companies across the life
sciences sector, including MedImmune, the global biologics research and development arm of AstraZeneca.
Definiens‘ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award
for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com
Safe Harbor Statement
This press release contains „forward-looking statements“ within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements relating to data being presented at the at the 2017 Society for
Immunotherapy of Cancer (SITC) held November 10-11, 2017 in National Harbor, MD. These „forward-looking
statements“ are based on management’s current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ materially and adversely from those described
or implied in the forward-looking statements.

Contact
Definiens AG
Heinz Oehl
Bernhard-Wicki-Straße 5
80636 München
Phone: +49 (0) 89 231180-00
E-Mail: press@definiens.com
Url: http://www.definiens.com

Medicine Wellness Health

biolitec® Medica 2017

FiLaC® confirms success with long-term study – New therapy method for endometriosis – Mobile LEONARDO® Mini laser can also be used for varicose veins

biolitec® Medica 2017

LEONARDO® laser family by biolitec® (Source: @ biolitec®)

Jena, November 13, 2017 – The success of FiLaC® therapy for the particularly painless and sphincter-friendly removal of anal fistulas from biolitec®, the technology leader in minimally invasive laser therapy, has been confirmed by a recently published long-term study. Very good results in first-line therapy (64.1%) and even better second-line treatment cure rates (85.5%). The study was carried out between October 2009 and July 2014 at the rectum and pelvic floor centre in Cologne (EBZ) by Dr. A. Wilhelm and other researchers on 117 patients.

With ELLA, the new treatment method for endometriosis, biolitec® is expanding its range of therapies in the field of gynaecology. The low-maintenance LEONARDO® DUAL 45 diode laser with its thin, high-quality flexible glass fibers and narrow laparoscopic tubes enables precise control of the laser beam. Initial results of a study confirm the rapid recovery of the AMH value and the significant maintenance of the ovarian reserve.

The biolitec® team will be presenting the whole range of the proven LEONARDO® laser family at booth H46 in hall 10.
The LEONARDO® laser family includes the LEONARDO® Dual series lasers in the 45 Watt, 100 Watt and 200 Watt power ranges, which are all characterized by the continuous use of the two wavelengths 980nm and 1470nm during the treatment. These lasers are the most versatile medical lasers available on the market today. They are suitable for phlebology and proctology as well as minimally invasive procedures in urology, gynaecology, orthopaedics, thoracic surgery and pneumology.

The innovative LEONARDO® Mini has also been part of the family for a year. Weighing only 900 grams this device is available in a version with a wavelength of 1470nm and as LEONARDO® Mini Dual with the two wavelengths 980nm and 1470nm. The small laser can also be used mobile in the established treatment methods of biolitec® for venous diseases, haemorrhoids, fistulas, a broad range of ENT disorders and gynaecological diseases. In addition, the new LEONARDO® Mini can carry out the proven ELVeS® Radial® 2ring laser therapy for the treatment of varicose veins. Sports injuries, inflammations and overloads can be treated quickly, precisely and non-invasively with the 15 Watt LEONARDO® Mini Athletic, which is available in the combinable wavelengths 810nm and 980nm.

The proven, unique XCAVATOR® laser fiber for the treatment of benign prostatic hyperplasia (BPH) has been significantly improved by biolitec®. Thanks to the optimized absorption capacity in water and hemoglobin, the new XCAVATOR® fiber enables the surgeon to work even faster and more precisely, so that the minimally invasive LIFE procedure of biolitec® can reduce side effects and pain even better than before.

biolitec® also opened its own branch office in Switzerland half a year ago, in order to be able to take into account the importance and high standards of the Swiss medical technology market. At www.biolitec.com, interested parties can find out more about the innovative laser therapies of biolitec®. From November 13 to 16 biolitec® will be represented at the Medica in Dusseldorf at booth H46 in hall 10.

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Medicine Wellness Health

Long-term study on biolitec®’s anal fistula therapy FiLaC®

Long-term study on the treatment of anal fistulas confirms that initial therapy with FiLaC® results in excellent primary and secundary cure rates

Long-term study on biolitec®

LEONARDO® DUAL 45 diode laser from biolitec® (Source: biolitec biomedical technology GmbH)

Jena, November 13, 2017 – A long-term study on the treatment of anal fistulas conducted on 117 patients with an average follow-up period of 25.4 months (overall study duration of 6-60 months) confirms a primary success rate of 64.1% from initial therapy using FiLaC®. The secondary cure rate (a second smaller procedure) was as high as 85.5%. Thus, the minimally invasive laser therapy FiLaC® is the modern, sphincter-sparing first-line treatment option for anal fistulas. Laser therapy can also be used for coccygeal fistulas.

In the FiLaC® therapy from the medical technology firm biolitec®, a flexible, radially emitting FiLaC® fiber is placed precisely at the internal orifice using a pilot beam, and the energy is emitted over the course of the fistular track. The efficient irradiation concept of the FiLac® fiber optimally uses the applied energy to close the fistular track. The treatment was performed using either a CERALAS® or a LEONARDO® DUAL 45 diode laser from the biolitec biomedical technology GmbH. This type of laser delivers energy with a wavelength of 1470 nm and an optimal absorption curve in water, which has the result of efficient local tissue shrinkage and protein denaturation. All areas of the surrounding musculature remain maximally preserved. Incontinence is generally avoided.

The study was published on March 7, 2017 by A. Wihelm et. al. It was conducted between October 2009 and July 2014 at the Cologne Rectal and Pelvic Floor Center (EBZ) on a treatment group of 117 patients with an anal fistula who were treated with the FiLaC® method. The objective of the study was the observation and evaluation of the treatment method of laser ablation over a long-term period. The FiLaC® procedure combines the objectives of successful fistula treatment, that is, clinical efficacy plus preservation of continence function.

A selection of the findings from the study:
-No case of incontinence of liquid stool occurred.
-The primary cure rate was 75/117 overall (64.1%); for cryptoglandular anal fistulas, it was 63.5%, and for fistulas secondary to Crohn“s disease, it was 69.2%.
-Of the 42 patients in whom FiLaC® did not work, 31 underwent a further operation (fistulectomy with sphincter muscle reconstruction or fistulectomy).
-The secondary cure rate (healing of the fistula at the end of the study period) was 103/117 overall (85.5%); for cryptoglandular anal fistulas it was 85.5%, and for fistulas secondary to Crohn“s disease, it was 92.3%.
-A significantly higher primary success rate was demonstrated for intersphincteric fistulas, with primary and secondary success-independent of age, sex, Crohn“s disease, number of previous operations, or the type of coverage using a skin flap.

The study was published in: A. Wilhelm / A. Fiebig / M. Krawczak (2017): Five years of experience with the FiLaCTM laser for fistula-in-ano management: long-term follow-up from a single institution; in: Techniques in Coloproctology (2017) 21:269-276.

Specialists can find further information about biolitec®“s innovative laser therapies at www.biolitec.com. Patients can find further information at www.info-anal-fistula.com and www.pilonidal-cysts.com or through the infoline at +49 6172 27159 11.

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Medicine Wellness Health

Definiens´ presents cutting edge data at the 32nd Annual SITC Congress

Washington, D.C., November 09, 2017 – With the start of the 32nd Annual Meeting (November 8th-12th) of the Society for Immunotherapy of Cancer (SITC) in National Harbor, MD, Definiens, the leader in Tissue Phenomics®, will exhibit key findings highlighting the impact of its end-to-end service portfolio for biomarker programs in immuno-oncology.
Definiens makes a strong contribution to the scientific program at SITC with two scientific talks and three poster presentations that highlight key insights obtained using Definiens“ technology. These key insights include highlighting the relevance of spatial analysis and the value of automated profiling of the tumor and its immune-context, which is presented in two posters that reveal the prognostic and predictive roles of CD8 and PD-L1.
Not only contextual information and spatial analysis play a critical role for the discovery of prognostic and predictive biomarkers, it is also the combination of information from genome and phenome that provides significant prognostic benefits. This is exemplified by Nathalie Harder in an oral presentation. Further third-party contributions describe the value of combining genomic and phenomic information with Definiens

technology for the characterization of the Tumor Micro-environment.
Definiens will also unveil its game-changing Immuno-Oncology Panel (IO-Panel) as parts of its groundbreaking new „Insights“-Services portfolio. This latest ready-to-use offering by Definiens enables standardized profiling with a Multiplex IHC Immuno-Oncology Panel. This combination of Definiens“ powerful Tissue Phenomics® technology and Mosaic Laboratories“ high-quality multiplex assays is able to provide unprecedented resolution of the tumor microenvironment which facilitates the identification of novel prognostic and predictive signatures. This novel data can be seen at the poster presentation and talk at the SITC Pre-Conference, delivered by DR. Svenja Lippok.
Join the Definiens experts at the sessions or at booth 333 to enrich your scientific curiosity and to learn more. A summary of presentations is found below.

Talks:
Combining Immunophenomics With Gene Expression Panel for Improved Prostate Cancer Recurrence Prediction
N. Harder 1, H. Hessel 2, M. Athelogou 1, A. Buchner 3, C. Stief 3, T. Kirchner 2, G. Schmidt 1, R. Huss 1
1 Definiens, Munich, Germany; 2 Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany; 3 Department of Urology, Ludwig-Maximilians-University, Munich, Germany
Session 209: Emerging Models & Imaging Saturday, November 11: 5:20 – 5:35 p.m.

Multiplex IHC Immuno-Oncology Panel for Standardized Profiling of the Immune Status Based on Spatial and Functional Characterization of the Tumor Microenvironment
Svenja Lippok
SITC Pre-conference „Immuno-Oncology Biomarkers: Today“s Imperatives for Tomorrow“s Needs“
Session 1: Biomarkers in Development, Wednesday, November 8: 8:25 a.m.

Posters:
# P83 Characterizing Cancers by Prevalence on the PD-L1/CD8 Axis
G. Schmidt 1, K. Steele 2, A. Meier 1, T. Herz 1, T. H. Tan 1, B. Higgs 2, S. Althammer 1, R. Huss 1
1 Definiens, Munich, Germany; 2 MedImmune, Gaithersburg MD, USA
Friday, November 10: 12:30 – 2 p.m. (Lunch) Friday, November 10: 6:30 – 8 p.m. (Reception)
# P4 The Prognostic and Predictive Roles of a CD8/ PD-L1 Signature in Cancer
S. Althammer 1, K. Steele 2, M. Widmaier 1, C. Brown 2, T. H. Tan 1, L. Rognoni 1, H. Kaplon 3, D. Friedrich 1, B. W. Higgs 2, G. Schmidt 1, K. Ranade 2, M. C. Dieu-Nosjean 3
1 Definiens, Munich, Germany; 2 MedImmune, Gaithersburg MD, USA; 3 INSERM, Paris, France
Saturday, November 11: 12:30 – 2 p.m. (Lunch) Saturday, November 11: 6:30 – 8 p.m. (Reception)
# P54 Multiplex IHC Immuno-Oncology Panel for Standardized Profiling of the Immune Status Based on Spatial Characterization of the Tumor Microenvironment
S. Lippok 1, K. Schneider 1, T. Wiestler 1, R. Korn 1, D. Medrikova 1, M. Widmaier 1, M. Hager 1, I. Kanchev 1, A. Masci 2, G. C. Sia 2, C. A. Kerfoot 2, L. M. Dauffenbach 2, F. Leiss 1

1 Definiens, Munich, Germany; 2 Mosaic Laboratories, Lake Forest, USA
Saturday, November 11: 12:30 – 2 p.m. (Lunch) Saturday, November 11: 6:30 – 8 p.m. (Reception)

About Definiens
Improving patient lives by unlocking the tissue phenome
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune
system for that purpose. Our mission is to accelerate breakthroughs in immuno-oncology by helping
pharmaceutical researchers better leverage tissue-based information through Definiens Tissue Phenomics® –
technology. Our expertise accelerates and deepens understanding of disease biology and immune system
mechanisms and allows to bring multi-omics data into a cancer-relevant context, which facilitates the
translation of new insights into novel therapies and treatment strategies. Our vision is to create unique and
actionable patient profiles through harmonized biomarkers for an individualized standard of care, where
patients experience fewer side effects and live longer. Definiens“ proven technology has been used in
thousands of projects, yielding results that have accelerated drug development and produced over 650 peerreviewed
publications.
Definiens is a member of the AstraZeneca group providing products and services to companies across the life
sciences sector, including MedImmune, the global biologics research and development arm of AstraZeneca.
Definiens‘ Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award
for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com
Safe Harbor Statement
This press release contains „forward-looking statements“ within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements relating to data being presented at the at the 2017 Society for
Immunotherapy of Cancer (SITC) held November 10-11, 2017 in National Harbor, MD. These „forward-looking
statements“ are based on management’s current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ materially and adversely from those described
or implied in the forward-looking statements.

Contact
Definiens AG
Heinz Oehl
Bernhard-Wicki-Straße 5
80636 München
Phone: +49 (0) 89 231180-00
E-Mail: press@definiens.com
Url: http://www.definiens.com

Medicine Wellness Health

Nuclear imaging targets the origins of back pain

World Spine Day 2017

(Vienna, October 16, 2017) Low back pain is an increasing and extremely widespread condition that becomes chronic in many patients, causing severe physical and emotional distress. Moreover, back pain is one of the leading causes of activity limitation and work absence all over the world and thus, has an enormous economic burden. Up to 80% of patients with back pain suffer from unspecific pain without identifiable cause. „But for those patients who are suspected to have a pain generator responsible for their complaints imaging techniques such as SPECT/CT can open up the path to efficient treatment,“ says Prof. Dr. Willm Uwe Kampen, expert from the Bone and Joint Committee of the European Association of Nuclear Medicine (EANM) on the occasion of the World Spine Day 2017.
Lately, molecular imaging using SPECT/CT (Single photon emission computed tomography / computed tomography) has become increasingly valuable in identifying pain generating lesions in patients suffering from back pain. This novel technique detects the raised metabolism that accompanies abnormal bone changes that cause back pain, and accurately localizes these to the anatomic sites that may be approached for treatment. „Identifying these physiological processes is essential since they precede anatomical changes by weeks, sometimes even months, and very often mark the actual targets for efficient treatment,“ says EANM expert Prof. Dr. Willm Uwe Kampen. This goal is achieved by tracers – weakly radioactively labelled substances the patient is injected with – and highly sensitive cameras which register the increased radioactive radiation emitted by the critical spots. The strength of hybrid SPECT/CT imaging lies in delivering such functional information on bone metabolism combined with the information from computed tomography (CT) which uses X-rays to assess the exact position and structure of the affected bones and joints. Thus, the combination of both methods (SPECT/CT) in a single examination has become state of the art in order to obtain a complete diagnostic picture whenever specific anatomical and physiological causes for back pain have to be assumed. „SPECT/CT offers the best of both worlds, as this novel hybrid imaging method combines the strengths of traditional CT with the proven benefits of nuclear medicine imaging, helping to establish a more accurate diagnosis in certain cases of severe back pain and opening up pathways for therapies with long-lasting effects. One of the fields where SPECT/CT has proven particularly helpful is the assessment of persisting or recurring back pain after spinal fusion surgery,“, says Prof. Kampen.
„This kind of treatment, which has become quite common in patients who suffer from constant back pain, sometimes causes follow-up complications. Persisting pain in these patients has multifarious reasons: Among them are postoperative infections, the improper placement of implants, broken screws, the loosening of hardware or the failure of bone fusion. Moreover, the rigid fixation of vertebrae can lead to increased stress on the adjacent spine segments. This might cause degeneration of the vertebrae above or below the fixed spine region or of facet and sacroiliac joints. While other imaging techniques such as Magnetic Resonance Imaging (MRI) provide precise and highly useful anatomical information this is often not sufficient since areas that are only anatomically suspicious are not necessarily the real origins of the back pain. In all these cases additional information on possible alterations in bone metabolic activity is crucial to establish what really induces the symptoms. SPECT/CT can provide all this information in a convenient single examination. Several studies show that SPECT/CT can track down pain causing conditions that are less easily – or not at all – captured by X-ray- and magnetic resonance images. „Ultimately, by improving the surgeon“s understanding of what is causing the patient“s symptoms, SPECT/CT has a profound role in selecting the right patient for the right treatment at the right time,“ according to Prof. Kampen.

Tracking down the culprits
The same advantages apply, of course, when it comes to examinations that are not connected to post-operative problems. CT and MRI provide reliable information on anatomical abnormalities such as disc herniation, degeneration of the vertebrae or potentially pathological changes of the bone marrow. But again, in an ageing European population it is becoming increasingly difficult to identify the culprit lesion on a background of multiple incidental degenerative findings. By localizing increased metabolic activities SPECT/CT helps filtering out the relevant pain generators. SPECT/CT has also proven valuable in patients with chronic low back pain who had undergone manual therapy without experiencing pain relief. SPECT/CT could identify facet joints that were metabolically active due to initial degeneration but without morphological changes seen in conventional radiography or even in CT. Subsequently, these patients received targeted treatment with facet joint injections which brought considerable alleviation, thus confirming the diagnostic value of SPECT/CT and the importance of functional in addition to anatomical imaging in order to select the right treatment. Thus, SPECT/CT opens up promising research paths that allow to assess and increase the efficiency of manual therapy.
„The relevance of SPECT/CT for identifying and staging cancer that has spread to bone has long been acknowledged. But recently it has become clear that SPECT/CT is an extremely useful problem-solving tool that can benefit a significant portion of patients with low back pain. In an increasingly cost-aware healthcare environment, being able to predict with SPECT/CT who will benefit from a particular treatment is an important prerequisite for an efficient treatment that in many cases can turn a life long burden into a curable condition,“ concludes Prof. Kampen.

Presseagentur für Medizinthemen

Contact
impressum health & science communication
Frank von Spee
Hohe Brücke 1
20459 Hamburg
Phone: 040 31786410
E-Mail: vonspee@impressum.de
Url: http://www.impressum.de

Medicine Wellness Health

Hallwang Clinic Private Oncology

The Hallwang Clinic is one of the leading establishments in integrated cancer therapy.

Hallwang Clinic Private Oncology

Hallwang Clinic

Working with state-of-the-art technology, the Hallwang Clinic is able to identify early signs of disease, and deliver targeted treatment. In addition, it has a broad range of experience in hematology, oncology, internal medicine and preventive medicine.

Once the clinic has established a person´s individual genetic profile, it can proceed to a targeted treatment. Based on various tests, an individual treatment strategy is designed including targeted antibodies, vaccination-strategies, chemotherapy and natural substances.

The Hallwang Clinic thinks that a relationship based on trust between doctor and patient is essential. It is created by personal discussion and careful clarification of Information.

The Hallwang Clinic offers 16 spacious single and twin bed rooms, with modern furnishings, some with balcony and a wonderful view of the enchanting natural surroundings. There is a generously dimensioned suite available on the top floor. All rooms and the suite are pleasantly light and airy, and all have large bathrooms. Each room has flat-screen tv, telephone and wi-fi connection. Patients are welcome to use the fitness room and physiotherapy department at any time at the Hallwang Clinic.

In order to achieve the best possible outcomes, the Hallwang Clinic stands to devise and implement an individual therapy plan for the patients. Treatment is carried out by a multidisciplinary team in cooperation with highly specialized doctors in human genetics, with immunologists, oncologists, radiologists, and dieticians/nutritionists. This treatment plan is supplemented by psychotherapeutic support and in-house physiotherapy.

Hallwang Clinic professional team
At the Hallwang Clinic, a professional team of nurses looks after its patients throughout the treatment. They act as a contact for any need, and create an atmosphere where every guest feels completely comfortable, and totally confident to be in good hands. All the staff is dedicated to making a stay at the Hallwang Clinic as pleasant as possible.

The Hallwang Clinic attaches great importance to a lovingly care in pleasant surroundings. A healthy lifestyle is very important. It takes pride in fresh and healthy food. To the greatest possible extent, it uses products that are sourced locally, which is lovingly prepared in a modern kitchen, always giving maximum consideration to nutritional values. And do not forget that we eat with our eyes, too. Meals are served in pleasant surroundings.

The Hallwang Clinic is a place of wellbeing. All year round, there is always something new to experience and discover.

Hallwang Clinic GmbH

Hallwang Private Oncology Clinic is situated in the lovely Black Forest of Southern Germany, and offers a range of personalised treatment strategies tailored to meet the patient´s individual needs as part of a comprehensive and holistic treatment program.

Our mission is to design a personalized treatment plan for every patient.

Contact
Hallwang Clinic GmbH
Maike Luz
Silberwaldstr. 34
72280 Dornstetten
Phone: + 49 7443 964 240
E-Mail: info@hallwang-clinic.com
Url: https://twitter.com/HallwangClinic

Medicine Wellness Health

New: Funny cartoons assist nuclear medicine physicians

Help for children during nuclear medical examinations

New: Funny cartoons assist nuclear medicine physicians

Sunny & Tim and their team help children through nuclear medical examinations (Source: Dr Ronald van Rheenen, Floris de Jonge)

Nuclear medical examinations can be stressful for patients – particularly for children. But Sunny the Isotope, Tim the Tracer and Rob the Receptor help reduce the strain. These cartoon characters, which have been developed by Ronald van Rheenen, expert of the European Association of Nuclear Medicine (EANM)., The Visual Education Project that gave birth to these characters provides child patients with age-appropriate information on the imaging examination. They make preparation rules easy to understand and lend a touch of fun and adventure to the procedure.
Undergoing a nuclear medical imaging examination can be quite a challenge. Some of these procedures last over an hour. During this time the patient is required to lie still on the imaging bed and avoid any motions as these might render the images being created useless for diagnostic purposes. For the same reason eating is sometimes not allowed prior to the imaging. All this is particularly demanding for children whose examinations make up an estimated 10 % of all nuclear medical examinations. They are also intimidated by the unfamiliar environment with its large nuclear medicine cameras whose detectors are placed very close to the body and somtetimes directly over the patient“s head. Concerns that the examination might be painful add to young patients“ anxiety. The accompanying parents are not always able to cheer up their child as they themselves might be distressed not knowing what to expect and which results the examination will provide.
In order to alleviate such fears and improve diagnostic accuracy through better cooperation of doctors and their young patients Dr Ronald van Rheenen, Nuclear Medicine Physician at the University Medical Hospital in Groningen (Netherlands) initiated the nonprofit Visual Education Project. Its „heoresheroes“ are Sunny the Isotope and Tim the Tracer, cartoon characters who appear in three different stories where they stand for the radioactive and the tracer substance that together form the radiopharmaceutical the patient is injected with. Tim takes Sunny on a journey through the body and guides him to Rob the Receptor who represents the target organ where the radiopharmaceutical accumulates. There Sunny shines his „special lights“ which reperesent the emitted radiation. This enables the „Photo Doctor“ to take pictures of the diseased areas. While this refers to diagnostic procedures one of the story lines also addresses nuclear medical therapy: This time Sunny & Tim are joined by Sam the Demolisherwho destroys the sick-spot. The stories are freely available as animations on YouTube and can be purchased as picture books (for links see below). Dr. van Rheenen, who pursues these educational activities in his free time, cooperates closely with the graphic designer Floris de Jonge. He brought the characters and storylines to life that Dr. van Rheenen had in mind. Meanwhile both have created three other storylines dealing with radiological imaging examinations.
The adventurous stories, straightforwardly told and catchily illustrated, not only help dissolve anxieties but also guide the childrens“ preparation before and their behaviour during examination. But the education material not only aims at very young readers. It might even help adults with low-health-literacy to understand the procedures and purposes of nuclear medicine. „Our decision to convey information in the form of visualized stories is motivated by the fact that most of the textual or verbal information which is provided prior to our examinations or therapy, is not correctly remembered – if at all,“ says Dr. van Rheenen. The project that started off three years ago as a local initiative based in Groningen has already spread its material considerably. The EANM and several European hospitals as well as patient platforms have the animations running on their websites or refer to it. With the support of the EANM the project is now on the verge of developing into a global initiative. Currently, versions in German, Spanish, French and Cantonese are under way and Dr. van Rheenen is dicussing possibilities of further dissemination with different National Nuclear Medicine Societies.
„It is essential to tailor explanations to the childrens“ grasping ability. Introducing the Visual patient education project to pediatric nuclear medicine and explaining the procedure with cartoon characters is a very promising tool to alleviate fears and apprehension and to transform the nuclear medicine study into a fun experience. This improved patient experience leads to improved cooperation resulting in studies of higher technical quality, ultimately leading to improved diagnostic accuracy“, says Dr. Zvi Bar-Sever, Chairman of the EANM pediatric committee.

Presseagentur für Medizinthemen

Kontakt
impressum health & science communication
Frank von Spee
Hohe Brücke 1
20459 Hamburg
040 31786410
vonspee@impressum.de
http://www.impressum.de

Medicine Wellness Health

Heart disease: nuclear imaging improves diagnostic

(Vienna, March 21, 2017) Heart catheterizations for assessing coronary heart disease are often unnecessary and can be replaced with functional cardiac imaging techniques. This is the result of a large-scale study recently conducted in the UK. „Functional cardiac imaging is less risky and less costly while providing accurate and reliable results. It is a good diagnostic starting point that should serve as gatekeeper for angiography,“ says Prof. Riemer H.J.A. Slart, cardiovascular expert of the European Association of Nuclear Medicine (EANM).

Chest pain might be a sign of coronary heart disease (CHD). If patients present with these symptoms it is essential to clarify whether this suspicion can be confirmed or not. Several diagnostic ways are available to detect CHD and determine whether revascularization – the restoration or improvement of the blood flow to the heart – is needed. A classical method is coronary angiography (CAG), an invasive technique that requires the catheterization of the heart. However, over the past decade two functional cardiac imaging techniques that create images of the heart and the coronary vessels have become important alternatives: Myocardial perfusion scintigraphy (MPS) and cardiovascular magnetic resonance (CMR). MPS is a nuclear imaging technique based on gamma-rays emitted by injected radiopharmaceuticals that accumulate in organs while CMR as a subfield of magnetic resonance imaging uses strong magnetic fields that interact with hydrogen atomic nuclei of the body.

MPS as well as CMR enable precise characterizations of the coronary system and allow for the localization of areas in the heart with an insufficient blood supply. They play a key role in diagnosing cardiovascular diseases, establishing prognoses and assessing the efficiency of possible therapies. The success of these imaging methods is even still growing as the underlying technological processes are continuously being improved. Compared to CAG these imaging techniques offer several benefits: They are non-invasive and less risky, they reduce the patients“ strain and help save costs. Despite these advantages, though, CAG is still much too frequently used at an early diagnostic stage in patients with suspected CHD. Too many of these patients undergo cardiac catheterization without obstructive coronary disease being found, a practice that exposes patients to unnecessary risks and creates avoidable costs. This has been shown by the CE-MARC 2 trial, a randomized study recently performed in six hospitals in the UK including 1202 patients with suspected coronary heart disease. Prof. Riemer H.J.A. Slart, cardiovascular expert of the EANM, points to the crucial result of the study: „Employing non-invasive functional cardiac imaging – MPS as well as CMR – results in a significant reduction of unnecessary angiography.“

Guidelines induce too many angiograms
The study divided the 1202 patients into three groups in order to compare three diagnostic strategies for clarification of suspected CHD: The first one used CMR and the second one MPS as a diagnostic starting point. The third strategy followed the guidelines of the British National Institute for Health and Care Excellence (NICE). In this latter group, those patients with a CHD pre-test likelihood of 10%-29% (defined as „low risk“ for CHD based on age, sex, symptoms, and medical history) were referred to cardiac computed tomography (CCT), while patients with a CHD pre-test likelihood of 30% to 60% (intermediate risk) were scheduled for MPS, and those with a high pre-test likelihood of over 60% were sent directly to coronary angiography. In the other two groups angiography was only provided as a possible follow-up examination. The researchers found that within 12 months 42,5 % of the patients belonging to the NICE guidelines group underwent coronary angiography while only 17,7 % of the CMR group and 16,2% of the MPS group did so. But the most important result is that 29% of the heart catheterizations carried out in patients of the NICE guidelines group turned out to be unnecessary but only 7,5% in the CMR group and 7,1% in the MPS group. The rate of clinical complications occurring after the 12 months test period did not differ between the three groups. One additional finding concerns CCT, which the NICE guidelines require for patients with low CHD risk. It turned out that the number of unnecessary angiograms that were performed on the basis of foregoing CCT examinations was significantly higher than that which were based on functional imaging results.

„It has become quite clear that coronary angiography needs to be restricted to cases that really require invasive examination. Functional imaging should be adopted easier and more frequently in the assessment of CHD, even in high risk groups. This is in the patients“ interest as well as for the benefit of the health care systems,“ says Prof. Slart. However, as the EANM expert points out, the new guidelines of the European Society of Cardiology (ESC) – which apply in several European countries – already fulfill these requests in part. While the British NICE guidelines define a CHD pre-test likelihood of 60% as threshold for immediate angiography the ESC guidelines require a pre-test likelihood of 85%. „The ESC guidelines certainly are a step in the right direction,“ says Prof. Slart.

What is nuclear medicine?

Presseagentur für Medizinthemen

Kontakt
impressum health & science communication
Frank von Spee
Hohe Brücke 1
20459 Hamburg
040 31786410
vonspee@impressum.de
http://www.impressum.de